Your search for "Brain and Nervous System" found 99 studies:
A RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

Protocol #: 19-1929

Location: University of Colorado Hospital

Neurological Screening of Controls in an Age-Related Macular Degeneration Registry

Protocol #: 19-1925

Location: University of Colorado Hospital

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

Protocol #: 19-1597

Location: University of Colorado Hospital

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy

Protocol #: 19-1620

Location: University of Colorado Hospital

A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)

Protocol #: 19-1599

Locations: Brain Imaging Center (BIC); University of Colorado Hospital

A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Protocol #: 19-1455

Location: University of Colorado Hospital

An investigation of immune biology and Alzheimers Disease-related biomarkers in asymptomatic, late life mild TBI

Protocol #: 19-1423

Location: University of Colorado Hospital

Feasibility of the Multiple Sclerosis Performance Test for assessment of functional performance measures in patients with Multiple Sclerosis

Protocol #: 19-1192

Location: University of Colorado Hospital

Comparative Effectiveness Research for Infantile Spasms V: 12Jan2017

Protocol #: 16-2408

Location: Childrens Hospital Colorado

Neurophysiological Correlates V: 31Jan18

Protocol #: 16-1480

Location: Childrens Hospital Colorado

Natural History of Rett Syndrome and Related Disorders

Protocol #: 15-2332

Location: Childrens Hospital Colorado

Gamma band neural stimulation and its effects on resting state networks

Protocol #: 19-1251

Locations: Brain Imaging Center (BIC); Department Specific Free Standing Clinic

A Two-year Prospective Natural History Study Examining the Use of Neuronal Injury Biomarkers in Autoimmune Encephalitis as a Potential Biomarker for Disease Activity and Severity

Protocol #: 19-0889

Locations: Brain Imaging Center (BIC); Childrens Hospital Colorado; Colorado Research Center; University of Colorado Hospital

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

Protocol #: 19-0675

Location: University of Colorado Hospital

A Multi-center, Prospective, Longitudinal, Digital Assessment Study of Disease Progression in Subjects with Early, Untreated Parkinson Disease (PD)

Protocol #: 19-0865

Location: University of Colorado Hospital

A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SUBCUTANEOUS OCRELIZUMAB ADMINISTRATION IN PATIENTS WITH MULTIPLE SCLEROSIS

Protocol #: 19-1040

Location: University of Colorado Hospital

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients With Generalized Myasthenia Gravis

Protocol #: 19-0772

Location: University of Colorado Hospital

An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis

Protocol #: 19-0150

Location: University of Colorado Hospital

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

Protocol #: 19-0520

Location: University of Colorado Hospital

Instrumentation of Huntington's Disease Motor Function Assessment

Protocol #: 19-0212

Location: University of Colorado Hospital

A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Protocol #: 19-0414

Location: University of Colorado Hospital

A 14-Week, Double-Blind, Randomized, Three-Arm, Parallel Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease (gLIDe)

Protocol #: 19-0478

Location: University of Colorado Hospital

A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma

Protocol #: 19-0423

Location: University of Colorado Hospital

AMPLATZERTM PFO Occluder Post Approval Study

This is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZERTM PFO Occluder in the post approval setting

To demonstrate safety of the AMPLATZERTM PFO Occluder by assessing the 30-day rate of device- or procedure-related serious adverse events including those that led to death and the effective by assessing the rate of recurrent ischemic stroke through 5 years

Protocol #: 19-6502

Location: Memorial Hospital Central

Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion

Protocol #: 19-0025

Location: University of Colorado Hospital

A Natural History Study of CMT1B, CMT2A, CMT4A and CMT4C

Protocol #: 18-2537

Location: University of Colorado Hospital

A MULTICENTER, OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENT

Protocol #: 19-0363

Location: University of Colorado Hospital

GORE? CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

This study will assess the safety and effectiveness of GORE? CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.

Protocol #: 19-6030

Locations: Harmony Campus; Medical Center of the Rockies

Bedside Resources to Gauge Intravascular Volume Status in Hypovolemic Infants in the Operating Room

Protocol #: 18-2513

Location: Childrens Hospital Colorado

Investigating cortical networks disruption and rehabilitation after traumatic brain injury

Protocol #: 19-0049

Locations: Colorado Research Center; Department Specific Free Standing Clinic

Gene Expression of Cerebral Aneurysms

In this study, we will collect tissue and blood from participants during their epilepsy surgery.

Protocol #: 19-0182

Location: University of Colorado Hospital

Investigating the Contribution of Peripheral versus Central Nervous System Immune Dysfunction to Cognitive Aging

Protocol #: 18-2607

Location: University of Colorado Hospital

Association of depth recordings from the temporal cortex with sleep pattern detection and characterization of sleep dysfunction in patients with refractory epilepsy.

Protocol #: 18-2806

Location: University of Colorado Hospital

Identifying relevant seizure biomarkers from RNS? System recorded electrocorticography for the development of optimized seizure detection algorithms

Protocol #: 18-2089

Location: University of Colorado Hospital

A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL201 IN SUBJECTS WITH PARKINSON'S DISEASE

Protocol #: 18-2423

Location: University of Colorado Hospital

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia Gravis

Protocol #: 18-2341

Location: University of Colorado Hospital

Safety and Efficacy Study of Elezanumab (ABT-555) in Relapsing Forms of Multiple Sclerosis

Protocol #: 18-2451

Location: University of Colorado Hospital

Safety and Efficacy Study of Elezanumab (ABT-555) in Progressive Forms of Multiple Sclerosis

Protocol #: 18-2152

Location: University of Colorado Hospital

Genomic Translation for ALS Care

Protocol #: 18-1768

Location: University of Colorado Hospital

A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS

Protocol #: 18-2047

Location: University of Colorado Hospital

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects with Spinocerebellar Ataxia

Protocol #: 18-1875

Location: University of Colorado Hospital

Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVERMS)

Protocol #: 18-1633

Location: University of Colorado Hospital

Clinical Outcome Measures in Friedreich's Ataxia

Protocol #: 18-1641

Location: University of Colorado Hospital

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study

Protocol #: 18-1336

Location: University of Colorado Hospital

Peripheral Inflammatory Cytokine Levels in Parkinson Disease

Protocol #: 18-1356

Location: University of Colorado Hospital

A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2-hydroxypropyl-a-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease

Protocol #: 18-0997

Location: University of Colorado Hospital

Conversational Speech in the Diagnosis of Neurocognitive Disorders

Protocol #: 18-0456

Location: University of Colorado Hospital

More than a Movement Disorder: Applying Palliative Care to Parkinson?s Disease v: 12/06/2017

Protocol #: 16-1400

Locations: Colorado Research Center; Department Specific Free Standing Clinic

Microburst VNS Therapy Feasibility Study in Patients with Refractory Epilepsy

Protocol #: 18-0995

Location: University of Colorado Hospital

Neurologic Music Therapy for enhancing fine motor control in Parkinson's Disease 16Apr2018

Protocol #: 16-2308

Location: University of Colorado Hospital

COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Protocol #: 18-0971

Location: Childrens Hospital Colorado

Ruptured Aneurysms Treated with Hydrogel Coils

To determine occlusion rates and safety when hydrogel coils are used in the treatment of ruptured intracranial aneurysms.

Protocol #: 18-6052

Location: Memorial Hospital Central

Multi-center, randomized, double-blinded assessment of Tecfidera? in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE)

Protocol #: 16-0121

Location: University of Colorado Hospital

A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease with Motor Fluctuations

Study is double blind and placebo controlled.

Protocol #: 18-0829

Location: University of Colorado Hospital

Automatic measurement of hand movements toward development of an objective assessment of primary motor symptoms in Parkinson?s disease

Protocol #: 15-1041

Location: University of Colorado Hospital

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

Protocol #: 18-0482

Location: University of Colorado Hospital

AMPLATZERTM PFO Occluder Post Approval Study

Protocol #: 17-2334

Location: University of Colorado Hospital

Diet and Relapses in Pediatric Multiple Sclerosis

Protocol #: 18-0393

Locations: Childrens Hospital Colorado; University of Colorado Hospital

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

Protocol #: 15-2388

Location: University of Colorado Hospital

Application of transcranial alternating current stimulation for modulation of sleep and cognitive performance

1).Optimize tACS parameters for duration, intensity and frequencies via utilization of EEG data recorded during tACS stimulation. 2)Determine whether recording artifacts introduced by tACS can confidently be removed from EEG signals. 3). Determine effects of tACS delivered with nested frequencies(multi-frequency signal) vs single frequency tACS, with regard to intrinsic EEG signal, for modulation of SWA coherence and power, as recorded in our overnight EEG sleep data. 4). Determine the cumulative effects of tACS delivered in multiple, consecutive nights on underlying EEG signals, sleep architecture, sleep quality and cognitive function among patients with MCI. 5). Determine if tACS is a viable treatment for disturbances of sleep and cognitive performance among patients with MCI. 6). Generate pilot data and manuscripts to support applications for larger randomized placebo-controlled clinical trials.

Protocol #: 16-1875

Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital

Multiple-Biopsy of Infiltrative Glioma (M-BIG) Study

Protocol #: 17-2111

Location: Childrens Hospital Colorado

Perceived palliative care needs of Huntington's disease patients

Protocol #: 18-0216

Location: University of Colorado Hospital

Clinical Trial Readiness for SCA1 and SCA3

Protocol #: 18-0020

Location: University of Colorado Hospital

A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients with Parkinson's Disease

Protocol #: 18-0113

Locations: Anschutz Health and Wellness; University of Colorado Hospital

Validation of a performance-based assessment of functional ability related to cognition in Parkinson's disease

Protocol #: 15-0170

Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital

Determining the Optimal Treatment Strategy for Patients who have Chronic Migraine with Medication Overuse

Protocol #: 16-2179

Location: University of Colorado Hospital

Risk factors in Early Multiple Sclerosis (RisE-MS)

among asymptomatic first degree relatives (FDRs), aged 18-30, of multiple sclerosis (MS) patients: 1: Determine the prevalence of brain/spine MRI lesions disseminated in space (DIS), consistent with MS 2: Gather data on potential risk factors or early signs related to MS development, including markers for: genes, immunological function, environmental factors, neuroaxonal damage, Vitamin D levels, lipid metabolism, activity levels, mood abnormalities, and cognitive function. From this, develop a risk factor score, incorporating all relevant potential markers of increased risk of DIS. 3: To use this pilot, cross-sectional study as a base for development of a long-term, longitudinal, multi-center study to determine genetic and environmental risks for pre-symptomatic MS 4: To create and maintain a biobank of specimens for future analysis as other potential biomarkers become available.

Protocol #: 17-1884

Location: University of Colorado Hospital

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy

Protocol #: 15-0657

Location: University of Colorado Hospital

A randomized, double blind, placebo-controlled parallel study of tolerability and efficacy of Cannabidiol (CBD) on tremor in Parkinson's disease

Protocol #: 17-2318

Location: University of Colorado Hospital

American Registry for Migraine Research

Protocol #: 17-2165

Locations: Lone Tree Medical Center; UCHealth Internal Medical Clinic - Lowry; University of Colorado Hospital

Phase 2 Study of Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke - CoBIS 2

The primary objective of the study is to determine, in a randomized, placebo controlled trial, the efficacy of a single intravenous (IV) infusion of unrelated donor UCB for improving functional outcomes in patients with ischemic stroke. The secondary objectives are as follows: 1.To describe the safety and tolerability of a single IV infusion of unrelated donor UCB in patients with ischemic stroke 2.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement of neurological symptoms following ischemic stroke 3.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement in quality of life and emotional and cognitive status in patients with ischemic stroke

Protocol #: 17-2136

Location: University of Colorado Hospital

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY OF CK-2127107 IN TWO ASCENDING DOSE COHORTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)

Protocol #: 17-1816

Location: University of Colorado Hospital

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease

Protocol #: 17-1532

Location: University of Colorado Hospital

Protocol I7S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) (The PRESENCE Study)

Protocol #: 17-1825

Location: University of Colorado Hospital

Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)

Protocol #: 17-1751

Location: University of Colorado Hospital

Transcranial electrical stimulation for the treatment of cervical dystonia

Protocol #: 17-1322

Locations: Colorado Research Center; Department Specific Free Standing Clinic

Calibrating free-living physical activity characteristics across functionally-limited populations using machine-learned accelerometer approaches

Regular physical activity is known to have positive effects on many health outcomes. In research, physical activity is often measured using activity monitors worn on the hip, wrist or ankle. These instruments determine how much physical activity a person does based on the amount of movement the person does. This is done with equations that use the data collected by the activity monitors. However, these equations are usually developed using measurements on healthy people. People who have movement disorders related to diseases such as Parkinson?s and Multiple Sclerosis, or conditions such as knee replacement, stroke, or arthritis have very different movement patterns than people without these diseases. Thus, the equations used to convert activity monitor data will not work well in people with these diseases or conditions. The purpose of this study is to develop equations to measure physical activity using activity monitors in people with movement limitations. Rather than creating specific equations for each individual disease and condition, we will perform simple tests to measure upper and lower body function, and then group people into different clusters based on these tests. Our preliminary studies show that these equations are more accurate than equations based on specific diseases or conditions.

Protocol #: 16-2706

Locations: CTRC-adult; University of Colorado Hospital

The modified Atkins diet in patients with drug resistant epilepsy and the responsive neurostimulator 09Aug2017

Protocol #: 17-0888

Location: University of Colorado Hospital

BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU Study

Protocol #: 15-2114

Locations: Memorial Hospital Central; University of Colorado Hospital

Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Protocol #: 17-1170

Location: University of Colorado Hospital

A PHASE 1B/2, MULTI-CENTER, DOUBLE-BLIND (PRINCIPAL INVESTIGATORS AND STUDY SUBJECTS BLINDED, SPONSOR UNBLINDED), PLACEBO-CONTROLLED, RANDOMIZED, SINGLE-ASCENDING DOSE STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DS-1040B IN SUBJECTS WITH ACUTE ISCHEMIC STROKE

Protocol #: 17-6183

Location: Memorial Hospital Central

Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis (IBM) - The International IBM Consortium Genetic Study

Protocol #: 17-1132

Location: University of Colorado Hospital

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) Study

Protocol #: 17-0873

Location: University of Colorado Hospital

Diagnostic and Rating Tools for Blepharospasm

Protocol #: 16-0017

Location: University of Colorado Hospital

MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM

Protocol #: 17-0679

Location: University of Colorado Hospital

Dystonia Coalition Project 1: Natural History and Biospecimen Repository for Dystonia

Protocol #: 11-0647

Location: University of Colorado Hospital

10-1311 DoneSave Functional connectivity of the motor network in two major subtypes of Parkinson Disease December 24,2015

Protocol #: 10-1311

Location: University of Colorado Hospital

Deep Brain Stimulation (DBS) of the Rostral Zona Incerta (rZI) for Parkinson's Disease (PD): Stereotactic Targeting and Clinical Efficacy

Protocol #: 16-1443

Location: University of Colorado Hospital

Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study

To demonstrate the superiority of MD1003, 300 mg/day, over placebo to clinically improve patients with progressive multiple sclerosis (MS).

Protocol #: 16-1727

Location: University of Colorado Hospital

Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders

Protocol #: 12-0968

Location: University of Colorado Hospital

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312

To demonstrate the efficacy of BAF312 relative to placebo in delaying the time to 3-month confirmed disability progression in patients with SPMS as measured by EDSS.

Protocol #: 13-2286

Location: University of Colorado Hospital

A Phase 3, Open-Label Study of the Safety, Efficacy, and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients with Unsatisfactory Control on Available Therapy.

To assess the long-term safety of apomorphine continuous infusion in advanced Parkinson?s disease (PD) patients who are unable to achieve adequate motor control despite optimal treatment with noninvasive therapy.

Protocol #: 15-1274

Location: University of Colorado Hospital

Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping Study

To create a repository of data and samples to be used to answer future research questions

Protocol #: 15-1774

Location: University of Colorado Hospital

A Phase IV Trial of Neuroprotection with ACTH in Acute Optic Neuritis

Protocol #: 13-0388

Location: University of Colorado Hospital

Wireless electroencephalography for continuous monitoring in the EEG LTM unit 12Apr2018

1. To evaluate the device?s ability to record wireless EEG from patients in the long-term EEG monitoring unit 2. To compare wireless EEG in these recordings to standard-of-care wired EEG

Protocol #: 15-0449

Location: University of Colorado Hospital

NAtalizumab for Prevention of Post-partum Relapses in patients with Multiple Sclerosis 09May2016

To assess the efficacy of IV administered natalizumab, monthly for 1 year, in preventing relapses during the postpartum period.

Protocol #: 16-0156

Location: University of Colorado Hospital

A Double-Masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

Protocol #: 14-0926

Location: University of Colorado Hospital

Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) Studies

To create a longitudinal collections of samples and data from: 1. Subjects with clinically-defined or highly suspicious for NMO or NMOSD; 2. Affected or unaffected relatives of subjects with clinically defined NMO or NMOSD; 3. Subjects with autoimmune diseases other NMO or NMOSD, such as multiple sclerosis, myasthenia gravis, Graves' disease, lupus, etc. 4. Healthy subjects

Protocol #: 13-3181

Location: University of Colorado Hospital

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran

To assess the safety and efficacy of long-term dosing with patisiran in transthyretin-mediated amyloidosis (ATTR) patients with familial amyloidotic polyneuropathy (FAP).

Protocol #: 15-1259

Location: University of Colorado Hospital